For an adult patient with major depressive disorder, should we start bupropion (Wellbutrin) extended‑release 150 mg tablet?

Bupropion Extended‑Release 150 mg for Major Depressive Disorder

Yes, start bupropion extended‑release (XL) 150 mg once daily in the morning for an adult with major depressive disorder, then increase to the target dose of 300 mg once daily after 4–7 days if tolerated. 1

Initial Dosing Protocol

• Begin with bupropion XL 150 mg once daily in the morning (with or without food) for the first 4–7 days to assess tolerability and minimize seizure risk. 1
• After 4 days, increase to the target therapeutic dose of 300 mg once daily in the morning, which is the FDA‑approved standard dose for major depressive disorder. 1
• Swallow tablets whole—do not crush, divide, or chew the extended‑release formulation, as this destroys the controlled‑release mechanism. 1

Expected Timeline for Clinical Response

• Monitor patient status within 1–2 weeks of initiation for worsening depression, suicidal ideation (especially in patients <24 years), agitation, or behavioral changes. 2
• Allow 6–8 weeks at the therapeutic dose (300 mg) before determining treatment adequacy; early improvement in energy may appear within 2–4 weeks, but full antidepressant effect requires the full 6–8‑week trial. 3, 2
• If no adequate response by 6–8 weeks, modify treatment by either increasing the dose (maximum 450 mg XL daily), switching to another antidepressant, or adding augmentation therapy (e.g., an SSRI). 2

Critical Safety Screening Before Prescribing

Absolute contraindications (do not prescribe bupropion if any are present): 1, 2

• Seizure disorder or any condition predisposing to seizures (e.g., prior head trauma, brain tumor, stroke, eating disorders such as bulimia or anorexia nervosa)
• Current or recent MAOI use (within 14 days of discontinuation)
• Abrupt discontinuation of alcohol, benzodiazepines, or antiepileptic drugs (precipitates withdrawal seizures)
• Uncontrolled hypertension (bupropion can elevate blood pressure and heart rate)

Dose Adjustments for Special Populations

• Moderate‑to‑severe hepatic impairment (Child‑Pugh 7–15): maximum dose is 150 mg every other day. 1
• Mild hepatic impairment (Child‑Pugh 5–6): consider reducing dose and/or frequency. 1
• Renal impairment (GFR <90 mL/min): reduce total daily dose by approximately 50% (e.g., 150 mg daily instead of 300 mg). 2, 1
• Older adults (≥65 years): start with lower doses (approximately 50% of standard adult dose, e.g., 37.5 mg daily, titrated by 37.5 mg every 3 days) to reduce adverse reactions. 3, 2

Clinical Advantages of Bupropion

• Significantly lower rates of sexual dysfunction compared with SSRIs (e.g., escitalopram, paroxetine), making it ideal for patients concerned about this side effect. 3, 2
• Minimal weight gain or even modest weight loss, unlike many other antidepressants. 2
• Particularly effective for depression with prominent apathy, low energy, or hypersomnia due to its dopaminergic and noradrenergic activity. 2, 4
• Dual benefit for patients who also want to quit smoking, as bupropion is FDA‑approved for smoking cessation. 2, 1

Monitoring Parameters

• Blood pressure and heart rate at baseline and periodically during the first 12 weeks, as bupropion can cause modest elevations. 2
• Suicidal ideation and behavioral changes, especially in the first 1–2 weeks and in patients <24 years (FDA black‑box warning for increased suicidal thoughts in this age group). 1, 2
• Seizure risk factors: the incidence of seizures at 300 mg/day is approximately 0.1% (1 in 1,000); risk increases markedly above 450 mg/day. 2

Common Pitfalls to Avoid

• Do not skip the 4–7 day lead‑in at 150 mg—rapid dose escalation increases seizure risk. 1
• Do not exceed 450 mg/day total (maximum dose for XL formulation), as seizure risk rises sharply above this threshold. 1
• Do not use in highly agitated patients—bupropion's activating properties can worsen agitation. 2
• Do not discontinue prematurely before 6–8 weeks unless significant adverse effects occur, as full therapeutic effect requires this duration. 2

Guideline Support

• The American College of Physicians (2016, reaffirmed 2024) recommends second‑generation antidepressants, including bupropion, as first‑line pharmacotherapy for major depressive disorder, with selection based on adverse‑effect profiles, cost, and patient preferences. 3
• The American Family Physician (2015) lists bupropion as a preferred agent due to its favorable adverse‑effect profile, particularly lower sexual dysfunction and weight gain compared with SSRIs. 3
• FDA approval for bupropion XL includes major depressive disorder and seasonal affective disorder. 1